Pipeline and Commercial Insight: Allergic Rhinitis - Immunotherapy Growth Surpassed by Generic Erosion by Datamonitor Now Available at ReportsandReports
Datamonitor estimates 2009 allergic rhinitis sales of $5 billion in the seven major markets, and forecasts a decline to $4.2 billion by 2019.
Dallas, TX, August 13, 2010 --(PR.com)-- ReportsandReports Announce it Will Carry Pipeline and Commercial Insight: Allergic Rhinitis - Immunotherapy growth surpassed by generic erosion Market Research Report in its Store.
Browse the complete Report on: http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-allergic-rhinitis-immunotherap/
Datamonitor estimates 2009 allergic rhinitis sales of $5 billion in the seven major markets, and forecasts a decline to $4.2 billion by 2019. The greatest threat to the market is generics, with drug classes having differing vulnerability to generic erosion. While the symptomatic treatment sales will decrease, immunotherapy sales are on the rise, with changing regulations dictating development.
Scope
- Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
- Assessment of key drug classes for allergic rhinitis, with analysis of impacting events and a 10 year sales forecast split by indication
- In-depth discussion of the role of immunotherapy in allergic rhinitis, with analysis of developments, regulations, and pipeline products
- Interactive patient-based forecasts of 3 immunotherapy products, with a discussion of their relative strengths and weaknesses
Highlights
Datamonitor estimates 2009 allergic rhinitis sales in the seven major markets of $5 billion. This is forecast to drop to $4.2 billion in 2019, driven by the entrance of cheap generics, most notably in the US. Oral antihistamines are the more vulnerable to generic erosion, while nasal corticosteroids are partially protected by their device.
Reformulation of molecules and combinations are common, but timing is key. In 2009, Merck’s Clarinex (desloratadine) had a quarter of Claritin’s (loratadine) peak sales, having launched after generics. Meda Pharma’s azelastine follow-on has seen more success launching prior to patent expiry and Meda Pharma is now combining the drug with a steroid.
Browse all Healthcare at http://www.reportsandreports.com/market-research/healthcare/
Browse all Datamonitor at http://www.reportsandreports.com/Publishers/datamonitor
Browse Latest Reports at: http://www.reportsandreports.com/LatestReport.aspx
Related Reports:
Commercial Insight: Antipsychotics - Revenues of depots and new agents will partially offset generic erosion
http://www.reportsandreports.com/market-reports/commercial-insight-antipsychotics-revenues-of-depots-and-new-a/
Pipeline and Commercial Insight: Insomnia - Future of innovative orexin drug class in doubt
http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-insomnia-future-of-innovative-/
Commercial Insight: Community Antibacterials - Pipelines wither as generic tidal wave takes its toll
http://www.reportsandreports.com/market-reports/commercial-insight-community-antibacterials-pipelines-wither-a/
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://www.reportsandreports.com/
http://reportsnreports.wordpress.com/
###
Browse the complete Report on: http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-allergic-rhinitis-immunotherap/
Datamonitor estimates 2009 allergic rhinitis sales of $5 billion in the seven major markets, and forecasts a decline to $4.2 billion by 2019. The greatest threat to the market is generics, with drug classes having differing vulnerability to generic erosion. While the symptomatic treatment sales will decrease, immunotherapy sales are on the rise, with changing regulations dictating development.
Scope
- Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
- Assessment of key drug classes for allergic rhinitis, with analysis of impacting events and a 10 year sales forecast split by indication
- In-depth discussion of the role of immunotherapy in allergic rhinitis, with analysis of developments, regulations, and pipeline products
- Interactive patient-based forecasts of 3 immunotherapy products, with a discussion of their relative strengths and weaknesses
Highlights
Datamonitor estimates 2009 allergic rhinitis sales in the seven major markets of $5 billion. This is forecast to drop to $4.2 billion in 2019, driven by the entrance of cheap generics, most notably in the US. Oral antihistamines are the more vulnerable to generic erosion, while nasal corticosteroids are partially protected by their device.
Reformulation of molecules and combinations are common, but timing is key. In 2009, Merck’s Clarinex (desloratadine) had a quarter of Claritin’s (loratadine) peak sales, having launched after generics. Meda Pharma’s azelastine follow-on has seen more success launching prior to patent expiry and Meda Pharma is now combining the drug with a steroid.
Browse all Healthcare at http://www.reportsandreports.com/market-research/healthcare/
Browse all Datamonitor at http://www.reportsandreports.com/Publishers/datamonitor
Browse Latest Reports at: http://www.reportsandreports.com/LatestReport.aspx
Related Reports:
Commercial Insight: Antipsychotics - Revenues of depots and new agents will partially offset generic erosion
http://www.reportsandreports.com/market-reports/commercial-insight-antipsychotics-revenues-of-depots-and-new-a/
Pipeline and Commercial Insight: Insomnia - Future of innovative orexin drug class in doubt
http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-insomnia-future-of-innovative-/
Commercial Insight: Community Antibacterials - Pipelines wither as generic tidal wave takes its toll
http://www.reportsandreports.com/market-reports/commercial-insight-community-antibacterials-pipelines-wither-a/
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://www.reportsandreports.com/
http://reportsnreports.wordpress.com/
###
Contact
ReportsandReports
Akshata Patil
+1-888-989-8004
http://www.reportsandreports.com/
Akshata Patil
+1-888-989-8004
http://www.reportsandreports.com/
Contact
Categories